Accurate assessment of the patient's prognosis is important for the overall management and treatment of AML. Patients can be stratified according to their risk of treatment resistance or treatment-related mortality, which will help guide the type and intensity of treatment.
Significant prognostic factors are:
The WHO subtype
- Certain cytogenetic subtypes have a much better prognosis than others (see subsequent pages).
Clinical Factors
- Age at diagnosis. Increased age is associated with a poorer prognosis, which also depends on the WHO subtype.
- Prior hematological malignancies. If the patient had a prior hematological malignancy, this carries a substantially poorer prognosis.
Other Variables (These variables can be significant in older patients.)
- Platelet count
- Serum creatinine
- Albumin
